Background: The function and the mechanism of long non-coding RNAs (lncRNAs) on the osteo-
inadequate bone height in the posterior maxilla. 4 Clinical studies have
shown that maxillary sinus augmentation can be reached by elevating the MSM with or without grafting, 5 which suggested that maxillary sinus membrane possesses osteogenic activity. Further studies have isolated and characterized maxillary sinus membrane stem cells (MSMSCs) in maxillary sinus membrane, which displayed stem cell properties similar to bone marrow mesenchymal stem cells (BMMSCs). 6 Our previous study demonstrated that MSMSCs could express MSC markers such as STRO-1, CD146, CD29. and CD44. 6 These cells can form colonies and differentiate into adipocytes, osteoblasts, and chondrocytes. 6 . Evidence further showed that MSMSCs can differentiate into osteoblasts both in vitro and in vivo, [7] [8] [9] [10] which represented a useful cell source of MSCs for bone tissue engineering.
Despite several researches on MSMSCs differentiation, the precise molecular mechanisms of osteogenic differentiation remain unclear.
Osteogenic differentiation of MSCs is controlled by a variety of signaling pathways. 11 Recently, long non-coding RNAs (lncRNAs) have emerged as important players in controlling stem cells fate and behavior. 12 For instance, a preliminary research found that a number of lncRNAs were significantly altered during the osteogenic differentiation of C3H10T1/2 cells. 13 Anti-differentiation ncRNA (ANCR) functions as a suppressor of osteogenic differentiation through a pathway suggested to involve enhancer of zeste homolog 2 (EZH2) and RUNX2. 14 Huang et al. revealed a H19/miR-675/TGF-b1/Smad3/HDAC pathway in regulating osteogenic differentiation of human MSCs. 15 In addition, lncRNA-POIR 16 and MEG3 17 were reported to regulate osteogenic differentiation through different mechanisms, whereas knockdown of HoxA-AS3 expression enhanced osteogenic differentiation and osteogenesis markers expression in MSCs. 18 These studies implied that lncRNAs both positively and negatively control the differentiation state of stem cells. Thus, the role of lncRNAs in MSMSCs differentiation is a great worthy studying question.
In our previous research, differential lncRNAs expression profiles in MSMSCs during osteogenic differentiation were established via microarray, and several upregulated lncRNAs between undifferentiated and osteogenic differentiated MSMSCs have been identified. 19 LncRNA-MODR/miR-454/RUNX2 pathway was suggested to regulate osteogenic differentiation of MSMSCs. 19 Meanwhile, lnc-NTF3-5 (ENST0000537192.1) displayed a significantly increase after 7 d of induction. Nevertheless, the function and the underlying molecular mechanism of lnc-NTF3-5 regulates the osteogenic differentiation of MSMSCs are still unknown.
To address these questions, this study aims to explore the role of lnc-NTF3-5 in osteogenic differentiation of MSMSCs and how it regulates the process. This study may provide a new molecular mechanism for osteogenic differentiation of MSMSCs and a new therapeutic target for bone regeneration in the posterior maxilla.
| M AT ER I AL S A N D M E TH ODS

| Informed consent
Studies were conducted in accordance with the guidelines of the Medical Ethics Committee of Sun Yat-Sen University and approved by the Sun Yat-Sen University Joint Institutional Review Board (IACUC-DB-16-1212). All donors provided informed written consent prior to specimen collection.
| Cell culture
HEK-293T cells were purchased from the American Type Culture Collection (ATCC). MSMSCs were isolated from normal human MSM according to our previously published methods. 6 Briefly, tissues were minced and digested with 3 mg/mL collagenase type I (Sigma, St. Louis, Missouri) and 4 mg/mL dispase (Roche, Mannheim, Germany) for 1 h at 378C. Then the samples were passed through a 70 lm strainer (Falcon, BD Labware, Franklin Lakes, New Jersey). Cells were supplemented into 75-cm 2 culture flasks (Costar, Cambridge, Massachusetts) with alpha modification of Eagle's medium (GIBCO BRL, Grand Island, New York), and then incubated in 5% CO 2 and 378C.
| Osteogenic differentiation
Osteogenic differentiation was conducted according to the instructions from the manufacturer (Invitrogen, Carlsbad, California). MSMSCs were plated into 6-well plates (Corning Life Sciences, Tewksbury, Massachusetts) at a density of 1 3 10 4 cells/well. BMP2 (100 ng/mL) was used to induce the differentiation when cells were reached 80% confluence.
| Quantitative real-time PCR
RNA was extracted from cells via TRIzol reagent (Invitrogen, Carlsbad, California), then cDNA was synthesized with SuperScript III reverse transcriptase kit (Qiagen, Valencia, California) according to the instruction from the manufacturer. The qRT-PCR was performed with TaqMan Universal PCR master mix (Applied Biosystems, Foster City, California) as described previously. 6 Relative mRNA and lncRNA expression were calculated with normalization to GAPDH, and U6 was used to normalize expression of miRNA. The primers used for amplification are listed in Table 1 .
| Western blot
Cells were washed with precooled PBS and lysed using RIPA buffer (Beyotime, Beijing, China For miRNA function study, mimics for miR-93-3p, miR-93-3p
inhibitor, as well as a nontargeting control miRNA mimic (nc RNA),
were obtained from RiboBio (Guangzhou, Guangdong, China). Then
MSMSCs were transfected in the presence of 8 mg/mL Polybrene (Santa Cruz Biotechnology, Dallas, Texas) overnight.
| Luciferase assays
The 1 
| In vivo transplantation
Animal experiments in this study were conducted in accordance with Approximately 4 3 10 6 MSMSCs were combined with 40 mg of deproteinized bovine bone (Bio-Oss; Geistlich, Wolhusen, Switzerland) and then placed in the subcutaneous pockets as described in previous studies. 20 Briefly, after the mice were anesthetized, approximately 2 cm incisions were made on the back of mice. Then the four groups of constructs were transplanted subcutaneously. The mice were sacrificed, and the transplants were harvested after 8 wk for further studies as described in our studies. 9 The transplants were fixed with 10% buffered formalin and decalcified with 10% ethylenediaminetetraacetic acid (pH 8.0) for 2 wk. Then the grafts were embedded in paraffin, sectioned into 3 lm sections, and stained with hematoxylin and eosin (H&E). The percentage of new bone formation per total section area was calculated using the average value of the three randomly selected parallel slices with Image Pro Plus 5.0 system (Media Cybernetics, Silver Springs, Maryland).
| Statistical analyses
All results were presented as the mean 6 standard deviations (SD) from at least in triplicate and were analyzed using two-tailed unpaired Student's t-test. The P values were adjusted using the Bonferroni correction for post hoc analysis for multiple group analysis. A P value < .05 was considered statistically significant. Alkaline Phosphatase (ALP) were also upregulated from day 0 to day 7 and declined on day 14 ( Figure 1C) . As indicated by RNA-FISH assay, lnc-NTF3-5 was found to be distributed in cytoplasm of MSMSCs, which was similar to 18S expression. In contrast, U6 was located in the nucleus ( Figure 1D ). RNA-FISH results suggested that lnc-NTF3-5 exert its function in cytoplasm. 
| MiR-93-3p is the target of lnc-NTF3-5
To further explore the underlying mechanism by which lnc-NTF3-5
regulates osteogenic differentiation, predicted targets of lnc-NTF3-5
were analyzed using miRnada, miRDB, and Target Scan software In addition, the expression of lnc-NTF3-5 in response to the miR-93-3p mimics and miR-93-3p inhibitor was also examined. QRT-PCR data revealed that lnc-NTF3-5 expression was significantly suppressed by miR-93-3p mimics ( Figure 4C ). During the process of osteogenic differentiation from day 0 to day 14, the expression of miR-93-3p was negatively correlated with lnc-NTF3-5 ( Figure 4D ).
To determine whether lnc-NTF3-5 directly regulates miR-93-3p, we generated luciferase reporter constructs. The miR-93-3p mimics and lnc-NTF3-5 wild-type or mutant reporter were transferred into 293T cells together. The results showed that the luciferase activity of lnc-NTF3-5 wild-type reporter was strongly suppressed by miR-93-3p mimics ( Figure 4E) . However, the lnc-NTF3-5 mutant reporter was not affected by miR-93-3p mimics ( Figure 4E ). As a final note, lnc-NTF3-5
and miR-93-3p expression levels were significantly higher in the anti- 
| D I SCUSSION
LncRNAs are generally defined as transcripts of longer than 200 nucleotides without evident of coding proteins and can regulate diverse cellular processes. 21 They are expressed at significantly lower levels but more cell type specific than protein-coding RNAs. 22 Our recent study found that lncRNAs can affect the osteogenic differentiation of MSMSCs, the top 5 lncRNAs were validated by qRT-PCR. 19 LncRNA-MODR plays a positive role in osteogenic differentiation of MSMSCs. 19 Similarly, researchers found that lncRNA-MEG can promote osteogenic differentiation as well. 17 This osteogenic promotion effect was demonstrated in human adipose-derived mesenchymal stem cells (ADMSCs) recently. There is now evidence that lncRNAs regulate gene expression and function at both transcriptional and post-transcriptional levels. 29 Four different mechanisms have been reported in lncRNAs and miRNAs interaction: miRNAs can bind to lncRNAs and reduce its stability; lncRNAs can act as sponges of miRNAs; lncRNAs can compete with miRNAs for binding to target mRNAs; and lncRNAs can generate miRNAs. 30 The interaction between lncRNAs and miRNAs represents a new aspect of physiological and pathological Many studies suggested that miRNAs can directly target the osteogenic master regulator RUNX2. 33 To elucidate the role of lnc-NTF3-5 in regulating osteogenic differentiation, bioinformatics analysis was performed to predict whether miR-93-3p can bind to the key transcription factor for osteogenesis RUNX2. Results found that miR-93-3p can directly bind to 2310-2316 nt of RUNX2 3 0 UTR, which suggested that miR-93-3p may regulate RUNX2 expression. Previous studies revealed that a plenty of miRNAs were involved in suppressing osteogenesis by targeting RUNX2, such as miR-103a, 34 miR-133a, 35 miR135a, 33 miR-204/211, 36 and miR-217. 37 miR-93-3p was reported to be upregulated in HIV-associated neurocognitive-disordered patients, 38 while downregulated in radioresistant nasopharyngeal carcinoma cells. 39 Meanwhile, miR-93-3p was suggested to be a potential biomarker of acute kidney injury (AKI) in intensive care units (ICU), and cardiac surgery (CS) patients since it was significantly downregulated during the days prior to AKI diagnosis. 
